Drug intelligence / Profile preview

clenbuterol

Development stage
Phase 2
Lead developer
Boehringer Ingelheim Vetmedica
Modality
Small Molecules
Administration
Oral, Inhalation, Intravenous
01

Overview

Clenbuterol is a sympathomimetic amine and a potent, long-acting beta2-adrenergic agonist used primarily as a bronchodilator for the treatment of asthma and other respiratory conditions in some countries outside the United States[1][3][5]. In the U.S., it is not approved for human use but is approved as Ventipulmin for treating airway obstruction in horses[1][4]. Clenbuterol acts by stimulating beta2-adrenergic receptor on bronchial smooth muscle, leading to bronchodilation. It also has decongestant properties and can increase energy expenditure, fat oxidation, and lean muscle mass while reducing body fat[6]. Due to these effects, it has been misused by athletes and bodybuilders for performance enhancement and weight loss. However, its use carries significant risks of adverse cardiovascular (e.g., tachycardia, hypertension) and neurological effects (e.g., tremors, anxiety)[1][2][7].

Brand names
Ventipulmin
Other names
clenbuterol hydrochloride
02

Targets

ADRB3 (β3)ADRB2 (β2)ADRB1 (β1)

Beyond the preview

Go deeper on clenbuterol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on clenbuterol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call